Amendments to the Claims:

This listing of claims will replace all prior versions and listings in the application:

Listing of Claims:

1-30   (Cancelled)

31 (New).   A method of reducing serum levels of triglycerides or VLDL, the method comprising administering a therapeutically effective amount of an autophagocytosis inducing compound to a patient in need thereof.

32 (New).   The method of Claim 31, wherein the autophagocytosis inducing compound is selected from a the group consisting of Map1LC3, GABARAP, GATE16, and Class III PI3 kinase.

33 (New).   Use of an autophagocytosis inducing compound for preparing a medicament useful for reducing serum levels of triglycerides or cholesterol.

34 (New).   The use of Claim 33, wherein the autophagocytosis inducing compound is selected from a the group consisting of Map1LC3, GABARAP, GATE16, and Class III PI3 kinase.

35 (New).   A method of treating or preventing a disorder in a patient in need of such treatment or prevention, the method comprising administering a therapeutically effective amount of an autophagocytosis inducing compound, wherein the disorder is selected from the a group consisting of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, atherosclerosis, arteriosclerosis, peripheral artery disease, coronary artery disease, congestive heart failure, myocardial ischemia, myocardial infarction, ischemic stroke, hemorrhagic stroke, restinosis, diabetes, insulin resistance, metabolic syndrome, renal disease, hemodialysis, glycogen storage disease type I, polycystic ovary syndrome, secondary hypertriglyceridemia, or a combination thereof.

36 (New).   The method of Claim 35, wherein the autophagocytosis inducing compound is selected from a the group consisting of Map1LC3, GABARAP, GATE16, and Class III PI3 kinase.

37 (New).   Use of an autophagocytosis inducing compound for the preparation of a medicament useful for treating or preventing a disorder selected from the a group consisting of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, atherosclerosis, arteriosclerosis, peripheral artery disease, coronary artery disease, congestive heart failure, myocardial ischemia, myocardial infarction, ischemic stroke, hemorrhagic stroke, restinosis, diabetes, insulin resistance, metabolic syndrome, renal disease, hemodialysis, glycogen storage disease type I, polycystic ovary syndrome, secondary hypertriglyceridemia, or a combination thereof.

38 (New).   The use of Claim 37, wherein the wherein the autophagocytosis inducing compound is selected from a the group consisting of Map1LC3, GABARAP, GATE16, and Class III PI3 kinase.

39 (New).   A method of identifying autophagocystosis modulating compounds, the method comprising:

(a) providing a control cell culture system and a test cell culture system;

(b) administering a test compound to cells in the test cell culture system; and

(c) assaying for an autophagocytosis marker in the control cell culture system and the test cell culture system, wherein an abnormal value for the autophagocytosis marker in the test cell culture system as compared to the control cell culture system indicates that the test compound modulates autophagocytosis.

40 (New).   The method of Claim 39, wherein the autophagocytosis marker is a VLDL or a VLDL precursor in an ER or a Golgi cell fraction.

41 (New).   The method of Claim 40, wherein the VLDL precursor is a PC or a PE moiety containing lipid.

5

42 (New).   The method of Claim 41, wherein the PC moiety containing lipid is 18:1(n-9) PC, wherein the PE moiety containing lipid is 20:5(n-3) PE.

43 (New).   The method of Claim 39, wherein c) assaying comprises detecting degree of co-localization of apoB100 and Map1LC3 by immunofluorescence.

44 (New).   A method of identifying autophagocystosis inducing compounds, the method comprising:

(a) providing a control cell culture system and a test cell culture system;

(b) administering a test compound to cells in the test cell culture system; and

(c) assaying for an autophagocytosis marker in the control cell culture system and the test cell culture system, wherein an abnormal value for the autophagocytosis markers in the test cell culture system as compared to the control cell culture system indicates that the test compound modulates autophagocytosis.

45 (New).   The method of Claim 44, wherein the autophagocytosis marker is a PC or a PE moiety containing lipid in a ER or a Golgi cell fraction.

46 (New).   The method of Claim 45, wherein the PC moiety containing lipid is 18:1(n-9) PC, wherein the PE moiety containing lipid is 20:5(n-3) PE.

47 (New).   The method of Claim 44, wherein c) assaying comprises detecting degree of co-localization of an apoB100 protein and a Map1LC3 protein by immunofluorescence.

48 (New).   The method of Claim 39, wherein the cells are hepatocytes or hepatoma cells.

49 (New).   The method of Claim 48, wherein the hepatocytes are rat hepatocytes which express a human apoB100 protein.

50 (New).   The method of Claim 48, wherein the hepatoma cells are rat hepatoma cells which express a human apoB100 protein.

51 (New).   The method of Claim 50, wherein the rat hepatoma cells are McA-RH-7777 cells.

6

52 (New).   The method of Claim 49, wherein the human apoB100 protein is fused with a tag.

53 (New).   The method of Claim 52, wherein the tag is a fluorescent protein.

54 (New).   The method of Claim 52, wherein the tag is tetra-cysteine having the sequence Cys-Cys-X-X-Cys-Cys, wherein X is any amino acid.